Pharmacokinetics and Pharmacodynamics — MCQs
On this page
Which of the following drugs can be administered through all routes?
Tubular secretion of a drug can be confirmed if its renal clearance is:
Atracurium is primarily eliminated by which mechanism?
A drug with a plasma half-life of 12 hours is administered twice a day. Steady-state plasma concentration reached is 300 mg/dl. Which of the following statements about this drug is not true?
All of the following cause inhibition of CYP3A except?
Which of the following drugs does not produce active metabolites?
Excretion of barbiturates in the urine can be increased by which of the following interventions?
The enzyme pseudocholinesterase acts on which of the following drugs?
ED50 is used for determining which of the following?
Apparent volume of distribution of a drug less than 5 liters implies that the drug is predominantly in which of the following compartments?
Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following drugs can be administered through all routes?
- A. Fentanyl (Correct Answer)
- B. Paracetamol
- C. Penicillin G
- D. Azithromycin
Explanation: **Explanation:** **Fentanyl** is the correct answer because it is a highly lipophilic opioid with high potency, allowing it to be formulated for virtually every route of administration. Its pharmacological profile supports: * **Parenteral:** IV, IM, and Epidural/Intrathecal (common in anesthesia). * **Transdermal:** Patches for chronic pain management. * **Transmucosal:** Buccal tablets, lozenges ("lollipop"), and sublingual sprays. * **Intranasal:** Used for breakthrough pain. * **Nebulization:** Occasionally used for dyspnea in palliative care. **Why the other options are incorrect:** * **Paracetamol:** While available as Oral, Rectal, and IV (Parven), it is **not** administered via transdermal or inhalational routes due to its chemical properties and the high dosage required for efficacy. * **Penicillin G:** It is acid-labile and destroyed by gastric acid, making it unsuitable for the **oral** route (unlike Penicillin V). It is primarily given IM or IV. * **Azithromycin:** It is available via Oral and IV routes. However, it lacks transdermal, sublingual, or routine inhalational formulations. **NEET-PG High-Yield Pearls:** * **Lipophilicity:** Fentanyl is 100 times more potent than morphine; its high lipid solubility is the key reason it can cross the skin (transdermal) and mucous membranes easily. * **First-Pass Metabolism:** Fentanyl undergoes extensive hepatic first-pass metabolism, which is why the oral (swallowed) route is ineffective, necessitating transmucosal (buccal/sublingual) delivery to bypass the liver. * **Context-Sensitive Half-Life:** Fentanyl’s duration of action increases significantly with prolonged infusions, a critical concept in ICU sedation.
Question 2: Tubular secretion of a drug can be confirmed if its renal clearance is:
- A. More than the glomerular filtration rate (GFR) (Correct Answer)
- B. Equal to the glomerular filtration rate (GFR)
- C. Less than the glomerular filtration rate (GFR)
- D. More than the volume of distribution
Explanation: ### Explanation The net renal clearance ($CL_{renal}$) of a drug is determined by three processes: **Glomerular Filtration + Tubular Secretion – Tubular Reabsorption.** [1] **1. Why Option A is Correct:** The Glomerular Filtration Rate (GFR) is approximately **125 mL/min**. If a drug is only filtered and neither secreted nor reabsorbed (like Inulin), its clearance equals the GFR [1]. If the renal clearance of a drug is **greater than 125 mL/min (or > GFR)**, it indicates that the drug is being actively added to the tubular fluid via **tubular secretion** in addition to being filtered at the glomerulus [1]. **2. Analysis of Incorrect Options:** * **Option B (Equal to GFR):** This occurs when a drug is filtered but undergoes **no net secretion or reabsorption** [1]. Examples include Inulin (exogenous) and Creatinine (endogenous, though it has minor secretion). * **Option C (Less than GFR):** This indicates that the drug is either **highly protein-bound** (not filtered) or, more commonly, undergoes **tubular reabsorption** after filtration (e.g., Glucose, Urea, or many lipid-soluble drugs) [1]. * **Option D (More than Volume of Distribution):** This is a non-sequitur. Renal clearance (a rate of volume per unit time, e.g., mL/min) and Volume of Distribution ($V_d$, a volume in Liters) are different parameters. $V_d$ relates to the extent of drug distribution in tissues, not the mechanism of renal excretion. **Clinical Pearls for NEET-PG:** * **Para-amino hippuric acid (PAH):** Has the highest renal clearance (~650 mL/min) because it is both filtered and completely secreted; it is used to measure **Renal Plasma Flow** [1]. * **Probenecid:** A high-yield drug that **inhibits the tubular secretion** of organic acids like Penicillin (increasing its duration of action) and Uric acid (acting as a uricosuric) [1]. * **Competition:** Two drugs using the same secretory transporter (e.g., OAT or OCT) can compete, leading to decreased clearance and potential toxicity.
Question 3: Atracurium is primarily eliminated by which mechanism?
- A. Renal excretion
- B. Hepatic elimination
- C. Nonenzymatic degradation (Correct Answer)
- D. All of the above
Explanation: **Explanation:** **Atracurium** is a benzylisoquinolinium neuromuscular blocking agent unique for its organ-independent elimination. The correct answer is **Nonenzymatic degradation**, specifically a process known as **Hofmann elimination**. 1. **Why Option C is Correct:** Atracurium undergoes spontaneous molecular breakdown at physiological pH and temperature (Hofmann elimination). It is also metabolized by **ester hydrolysis** via non-specific plasma esterases. Because it does not rely on organ function for clearance, it is the drug of choice for patients with **renal or hepatic failure**. 2. **Why Other Options are Incorrect:** * **Option A & B:** While most muscle relaxants (like Vecuronium or Pancuronium) depend on the kidneys or liver for excretion, Atracurium’s primary pathway bypasses these organs. Impairment in renal or hepatic function does not significantly prolong its duration of action. * **Option D:** Since the primary and clinically significant route is nonenzymatic, "All of the above" is incorrect. **High-Yield Clinical Pearls for NEET-PG:** * **Laudanosine Toxicity:** Hofmann elimination produces a metabolite called *Laudanosine*. In high concentrations (prolonged infusions), it can cross the blood-brain barrier and act as a **CNS stimulant**, potentially causing **seizures**. * **Cisatracurium:** An isomer of atracurium that is more potent, produces less laudanosine, and does not cause **histamine release** (unlike atracurium, which can cause flushing and hypotension). * **Temperature/pH Sensitivity:** Since Hofmann elimination is spontaneous, the rate of degradation increases with hyperthermia/alkalosis and decreases with hypothermia/acidosis.
Question 4: A drug with a plasma half-life of 12 hours is administered twice a day. Steady-state plasma concentration reached is 300 mg/dl. Which of the following statements about this drug is not true?
- A. Plasma concentration will be approximately 260 mg/dl after three half-lives of initiation of therapy.
- B. Intravenous administration will always achieve a higher concentration than the oral route. (Correct Answer)
- C. After changing the dose, plasma concentration should be measured after 3 days.
- D. Doubling the dose will double the plasma concentration after 3 days.
Explanation: ### Explanation **1. Why Option B is the Correct (False) Statement:** The statement "Intravenous administration will **always** achieve a higher concentration than the oral route" is incorrect because steady-state concentration ($C_{ss}$) depends on the **bioavailability ($F$)** and the **dose**. If the oral dose is adjusted to compensate for low bioavailability (e.g., giving a much larger oral dose than the IV dose), the resulting plasma concentration can be identical. Furthermore, for drugs with 100% bioavailability (e.g., Levofloxacin, Linezolid), the plasma concentrations for both routes are virtually the same. **2. Analysis of Other Options:** * **Option A (True):** Steady state is reached in 4–5 half-lives. After 1 half-life, concentration is 50% of $C_{ss}$; after 2, it is 75%; and after **3 half-lives**, it is **87.5%**. Calculation: $0.875 \times 300 \text{ mg/dl} = 262.5 \text{ mg/dl}$, which is approximately 260 mg/dl. * **Option C (True):** To measure a new steady state after a dose change, we wait 4–5 half-lives. Here, $t_{1/2} = 12$ hours. Thus, $5 \times 12 = 60$ hours. Since 60 hours is roughly **2.5 to 3 days**, measuring at 3 days is clinically appropriate. * **Option D (True):** Most drugs follow **First-order kinetics**, where the $C_{ss}$ is directly proportional to the dose. Doubling the dose will double the steady-state concentration once the new equilibrium is reached (after ~3 days). **Clinical Pearls for NEET-PG:** * **Steady State:** It takes **4–5 half-lives** to reach steady state, regardless of the dose or frequency (provided the dose is constant). * **Plateau Principle:** The time to reach steady state depends *only* on the half-life, not on the dose. * **Bioavailability ($F$):** For IV drugs, $F = 1$ (or 100%). * **High-Yield Formula:** $C_{ss} = \frac{\text{Bioavailability} \times \text{Dose}}{\text{Interval} \times \text{Clearance}}$.
Question 5: All of the following cause inhibition of CYP3A except?
- A. Saquinavir (Correct Answer)
- B. Ritonavir
- C. Itraconazole
- D. Erythromycin
Explanation: ### Explanation The Cytochrome P450 (CYP) system, specifically the **CYP3A4** isoform, is responsible for the metabolism of over 50% of clinically used drugs. Understanding its inhibitors and inducers is a high-yield topic for NEET-PG. **Why Saquinavir is the correct answer:** While most Protease Inhibitors (PIs) are known to interact with the CYP system, **Saquinavir** is primarily a **substrate** of CYP3A4 rather than a potent inhibitor. In clinical practice, Saquinavir has such poor bioavailability that it must be "boosted" by another PI (Ritonavir) to reach therapeutic levels. Unlike Ritonavir, it does not significantly inhibit the metabolism of other drugs. **Analysis of Incorrect Options:** * **Ritonavir (Option B):** This is the **most potent inhibitor** of CYP3A4 among the protease inhibitors. It is used pharmacologically in "low doses" specifically to inhibit the metabolism of other PIs (like Lopinavir or Saquinavir), thereby increasing their plasma concentrations (PK boosting). * **Itraconazole (Option C):** Azole antifungals (especially Ketoconazole and Itraconazole) are classic, potent inhibitors of CYP3A4. They frequently cause drug-drug interactions with statins and warfarin. * **Erythromycin (Option D):** Macrolide antibiotics (except Azithromycin) are notorious CYP3A4 inhibitors. They can lead to toxicity of co-administered drugs like Theophylline or Carbamazepine. **NEET-PG High-Yield Pearls:** * **Mnemonic for CYP3A4 Inhibitors (VITAMIN G):** **V**erapamil, **I**traconazole (and other azoles), **T**elithromycin/Tetracycline, **A**miodarone, **M**acrolides (excluding Azithromycin), **I**nhibitors of HIV Protease (**Ritonavir**), **N**efazodone, **G**rapefruit juice. * **The "Azithromycin Exception":** Among macrolides, Azithromycin does not inhibit CYP enzymes and is the safest choice regarding drug interactions. * **Rifampicin** is the most potent universal **inducer** of CYP enzymes.
Question 6: Which of the following drugs does not produce active metabolites?
- A. Enalapril
- B. Lisinopril (Correct Answer)
- C. Prednisone
- D. Sulfasalazine
Explanation: The core concept tested here is the difference between **active drugs** and **prodrugs**. A prodrug is pharmacologically inactive and must be metabolized (usually by the liver) into an active metabolite to exert its effect [2]. **1. Why Lisinopril is the correct answer:** Most ACE inhibitors are prodrugs (e.g., Enalapril to Enalaprilat) to improve oral bioavailability. However, **Lisinopril** and **Captopril** are the two major exceptions. Lisinopril is an active drug; it is not metabolized by the liver and is excreted unchanged in the urine. Therefore, it does not produce active metabolites [1]. **2. Analysis of Incorrect Options:** * **Enalapril (Option A):** It is a prodrug converted by hepatic esterases into its active form, **Enalaprilat** [1]. * **Prednisone (Option C):** It is a corticosteroid prodrug that must be converted in the liver by the enzyme 11β-HSD to its active form, **Prednisolone** [3]. * **Sulfasalazine (Option D):** It is broken down by colonic bacteria into **Sulfapyridine** and **5-aminosalicylic acid (5-ASA)**; the latter is the active moiety used in treating Ulcerative Colitis [4]. **High-Yield Clinical Pearls for NEET-PG:** * **ACE Inhibitor Exceptions:** Remember the mnemonic **"CL"** (Captopril and Lisinopril) as the ACE inhibitors that are *not* prodrugs. * **Lisinopril** is preferred in patients with liver disease because it does not require hepatic activation. * **Active Drugs vs. Prodrugs:** Most drugs are active as administered. Common prodrugs to remember for exams include Levodopa (to Dopamine), Cyclophosphamide (to Phosphoramide mustard), and Clopidogrel.
Question 7: Excretion of barbiturates in the urine can be increased by which of the following interventions?
- A. Diuretics
- B. Urinary alkalinization (Correct Answer)
- C. Urinary acidification
- D. Hemodialysis
Explanation: **Explanation:**The excretion of barbiturates (specifically Phenobarbital) is increased by **urinary alkalinization** through the principle of **ion trapping**.**1. Why Urinary Alkalinization is Correct:**Barbiturates are **weakly acidic** drugs. According to the Henderson-Hasselbalch principle, acidic drugs remain non-ionized in acidic environments and become **ionized (charged)** in alkaline environments. By administering Sodium Bicarbonate ($NaHCO_3$) to alkalinize the urine, the barbiturate molecules become ionized. Since ionized drugs are lipid-insoluble, they cannot be reabsorbed across the renal tubular epithelium back into the blood and are instead "trapped" in the tubular lumen and excreted [1].**2. Why Other Options are Incorrect:** * **Diuretics (A):** While forced diuresis increases urine volume, it is significantly less effective than altering pH for weak acids and is no longer the primary recommendation due to the risk of pulmonary edema. * **Urinary Acidification (C):** This would keep the acidic barbiturate in a non-ionized, lipid-soluble state, promoting its reabsorption into the systemic circulation and worsening toxicity. (Acidification is used for weak bases like Amphetamines). * **Hemodialysis (D):** While effective for severe poisoning, it is an invasive procedure. Urinary alkalinization is the first-line pharmacological intervention for enhancing renal clearance.**Clinical Pearls for NEET-PG:** * **Mnemonic:** **A**cidic drugs are excreted in **A**lkaline urine (e.g., Barbiturates, Salicylates, Methotrexate). * **Agent used:** Intravenous **Sodium Bicarbonate** is the drug of choice for urinary alkalinization. * **Target pH:** The goal is to maintain a urinary pH between **7.5 and 8.5**. * **Note:** Only long-acting barbiturates like **Phenobarbital** are significantly excreted by the kidneys; short-acting ones are primarily metabolized by the liver.
Question 8: The enzyme pseudocholinesterase acts on which of the following drugs?
- A. Decamethonium
- B. Tubocurarine
- C. Gallamine
- D. Suxamethonium (Correct Answer)
Explanation: **Explanation:** **1. Why Suxamethonium is Correct:** Suxamethonium (Succinylcholine) is a depolarizing neuromuscular blocker. Its short duration of action (5–10 minutes) is due to its rapid metabolism by **Pseudocholinesterase** (also known as Butyrylcholinesterase or Plasma Cholinesterase), found in the liver and plasma. Unlike Acetylcholinesterase (found at the synaptic cleft), pseudocholinesterase is responsible for hydrolyzing esters like suxamethonium and local anesthetics (e.g., procaine). **2. Why the Other Options are Incorrect:** * **Decamethonium (A):** Although it is a depolarizing blocker like suxamethonium, it is **not** metabolized by pseudocholinesterase. It is excreted unchanged in the urine. * **Tubocurarine (B) & Gallamine (C):** These are non-depolarizing neuromuscular blockers. Tubocurarine is primarily excreted in the urine and bile, while Gallamine is eliminated almost entirely unchanged by the kidneys. They do not rely on cholinesterase enzymes for termination of action. **3. High-Yield Clinical Pearls for NEET-PG:** * **Succinylcholine Apnea:** This occurs in patients with a **genetic deficiency** or atypical variant of pseudocholinesterase (detected by a low **Dibucaine Number**). In these patients, suxamethonium is not metabolized, leading to prolonged muscle paralysis and respiratory failure. * **Site of Synthesis:** Pseudocholinesterase is synthesized in the **liver**; its levels may drop in chronic liver disease, leading to prolonged action of suxamethonium. * **Anticholinesterases:** Drugs like Neostigmine inhibit both types of cholinesterases. Therefore, Neostigmine **potentiates** (prolongs) the phase I block of suxamethonium rather than reversing it.
Question 9: ED50 is used for determining which of the following?
- A. Potency (Correct Answer)
- B. Efficacy
- C. Safety
- D. Toxicity
Explanation: **Explanation:** **1. Why Potency is Correct:** Potency refers to the amount of drug (dose) required to produce an effect of a given intensity. It is measured by the **ED50 (Median Effective Dose)**, which is the dose required to produce a specified therapeutic effect in 50% of the population (in quantal dose-response curves) or the dose that produces 50% of the maximal response (in graded curves). A drug with a lower ED50 is considered more potent because a smaller dose is needed to achieve the same effect. **2. Why Other Options are Incorrect:** * **B. Efficacy:** This refers to the maximum effect ($E_{max}$) a drug can produce, regardless of dose. It is determined by the height of the dose-response curve, not the ED50. * **C. Safety:** Safety is determined by the **Therapeutic Index (TI)**, which is the ratio of the median lethal dose to the median effective dose ($TI = LD_{50} / ED_{50}$). * **D. Toxicity:** This is measured by the **TD50 (Median Toxic Dose)**, which is the dose that produces a specific toxic effect in 50% of the population. **Clinical Pearls for NEET-PG:** * **Potency vs. Efficacy:** Efficacy is clinically more important than potency. For example, Furosemide is more efficacious than Thiazides (it can remove more fluid), even if a Thiazide might be more potent (requiring fewer milligrams). * **Drug Comparison:** On a dose-response graph, if Curve A is to the **left** of Curve B, Drug A is more **potent**. If Curve A is **higher** than Curve B, Drug A has higher **efficacy**. * **Therapeutic Window:** The range between the minimum effective therapeutic concentration and the minimum toxic concentration.
Question 10: Apparent volume of distribution of a drug less than 5 liters implies that the drug is predominantly in which of the following compartments?
- A. Extracellular fluid (Correct Answer)
- B. Total body water
- C. Intracellular fluid
- D. Intravascular fluid
Explanation: **Explanation:** The **Apparent Volume of Distribution ($V_d$)** is a theoretical volume that represents the degree to which a drug distributes into body tissues compared to the plasma. It is calculated as: $V_d = \text{Total amount of drug in body} / \text{Plasma concentration}$. **Why Option A is Correct:** In a standard 70 kg adult, the **plasma volume (intravascular fluid)** is approximately **3–4 Liters**. If a drug has a $V_d$ of less than 5 Liters, it indicates that the drug is largely confined to the vascular compartment. This typically occurs with drugs that have high molecular weights (e.g., Heparin) or those that are extensively bound to plasma proteins (e.g., Warfarin), preventing them from leaking out into the interstitial or intracellular spaces. **Analysis of Incorrect Options:** * **B. Total Body Water (~42 L):** Drugs with a $V_d$ around 40–50 L (e.g., Ethanol, Phenytoin) distribute uniformly throughout all body water compartments. * **C. Intracellular Fluid (~28 L):** Drugs do not typically stay solely in the intracellular fluid; a high $V_d$ (exceeding total body water, e.g., Digoxin, Chloroquine) suggests the drug is sequestered deep in tissues/organs. * **D. Intravascular fluid:** While a $V_d$ < 5 L specifically describes the intravascular space, in the context of standard pharmacological classification and the provided options, "Extracellular fluid" (which includes plasma) is the conventional answer for drugs restricted by size or protein binding. *Note: If both were options, Plasma/Intravascular is technically more precise for <5L, but ECF (~14L) is the broader category often tested.* **High-Yield NEET-PG Pearls:** * **Low $V_d$ (< 5 L):** Drug is in plasma (e.g., Heparin, Warfarin, Insulin). These drugs are easily removed by **hemodialysis**. * **Medium $V_d$ (15–40 L):** Drug is in ECF (e.g., Aminoglycosides, Mannitol). * **High $V_d$ (> 42 L):** Drug is sequestered in tissues (e.g., Digoxin, Chloroquine, Morphine). These drugs have a long half-life and **cannot** be removed by dialysis.
Practice by Chapter
Absorption and Bioavailability
Practice Questions
Drug Distribution and Protein Binding
Practice Questions
Biotransformation and Metabolism Pathways
Practice Questions
Renal and Non-renal Excretion
Practice Questions
Compartment Models
Practice Questions
Dose-Response Relationships
Practice Questions
Drug Efficacy and Potency
Practice Questions
Drug Tolerance and Tachyphylaxis
Practice Questions
Population Pharmacokinetics
Practice Questions
Pharmacokinetic Variability
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free